Agios Pharmaceuticals Operating Income

The latest operating income for AGIO is $-460M as of June 2026. That compares with $-460M in the prior-year period — up 0.5% year over year. Investors often review this figure alongside Agios Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGIO's operating income moved from $-460M to $-460M — a 0.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Agios Pharmaceuticals's operating scale or balance-sheet position.

A operating income figure of $-460M for AGIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AGIO's operating income ($-460M), review year-over-year change from $-460M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Agios Pharmaceuticals's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.